Marijuana-based Drugs: Innovative Therapeutics or Designer Drugs of Abuse?

Table 1

Strategies to Circumvent Adverse Effects of CB1R Ligands

Strategy Representative Compound Observed Effect(s) Reference
Peripherally Restricted CB1R Ligands URB-447 (CB1 antagonist) ↓ Body Wt (72)
SAB-378 (CB1 agonist) ↓ GI Motility (73)
CB1R Allosteric Modulators ORG-27569 (Negative AM) ↑ Affinity (74)
↓ Function
PSNCBAM-1 (Negative AM) ↓ Body Wt (77)
↓ Excitability
FAAH Inhibitor URB-597 ↑ AEA (83)
MGLL Inhibitor JZL-184 ↑ 2AG (84)
CB1R Neutral Antagonist AM-4113 ↓ Body Wt (89)
↓ Adverse Effects

This Article

  1. MI February 2011 vol. 11 no. 1 36-51